Company intelligence / Profile preview

METRO Hotels

Worcester, Massachusetts, United Statesmetrohotelsf.com ↗

Ownership: Private
Development stage: Other

Overview

Metro International Biotech's lead compound, MIB‑626, is currently in Phase II clinical trials for COVID‑19, acute renal failure (acute kidney injury), and mild dementia. The company has generated robust preclinical data supporting the broad therapeutic potential of modulating NAD+ levels and has developed scalable manufacturing capabilities for its oral dosage formulations. Ongoing Phase II trials are being conducted at leading hospitals.

Therapeutic areas: NephrologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on METRO Hotels.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METRO Hotels.

Explore the full profile